Skip to content Skip to footer
Subscribe Now
Top Performing Drug – Perjeta (January Edition)
INSIGHTS+

Top Performing Drug – Perjeta (January Edition)

Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Perjeta and prepared a curated analysis report for our readers  Perjeta is indicated for the treatment of HER2-positive metastatic breast cancer, neoadjuvant HER2-positive breast cancer, Adjuvant HER2-positive breast cancer PharmaShots presents a concise…
January 30, 2024

Read more

ThoughtSpot_Saurabh Chaubey9
THOUGHTSPOT

Targeted Therapy in Oncology

Shots:  The oncology domain accounts for more than 50% of ongoing clinical trials. The global oncology drug market was valued at $185B in 2022 and is predicted to reach $205B by 2030 with a 13% CAGR   Targeted therapy targets specific genes and proteins to prevent them from growing and spreading. In 2022, the market size…
January 3, 2024

Read more

Top Performing Drug – Cosentyx (November Edition)
INSIGHTS+

Top Performing Drug – Cosentyx (November Edition)

Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Cosentyx and prepared a curated analysis report for our readers  Cosentyx is indicated for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is a human IgG1κ mAb which targets interleukin (IL)-17A    PharmaShots presents a…
November 22, 2023

Read more

New Drug Designations - October 2023
INSIGHTS+

New Drug Designations – October 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA and the EMA. This month’s report includes 2 biological drugs, 12 small molecules, 10 cell and gene therapies, 2 vaccines, 1 peptide, 1 exosome-based therapy and 3 devices  HuidaGene Therapeutics’ HG204 CRISPR RNA-editing therapy, focused on the treatment of MECP2 duplication…
November 20, 2023

Read more

New Drug Designations - September 2023
INSIGHTS+

New Drug Designations – September 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, and China. This month’s report includes 10 biological drugs, 15 small molecules, 5 cell and gene therapies, 4 devices, 1 vaccine and 1 microbiota  MicuRx’ Contezolid and Contezolid acefosamil, focused on the treatment of Diabetic…
October 16, 2023

Read more

Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Health Equity: A Pressing Need

Shots:  With half of the World's population devoid of primary healthcare facilities, health equity is indeed an indispensable need of the present. With health equity instated, potentially everyone can attain the highest level of health. It means no more deaths from vaccine-preventable diseases, and a healthy equilibrium in the physical, mental, and social aspects of…
October 10, 2023

Read more

VIEWPOINTS_Samantha Kerr_2023
VIEWPOINTS

Samantha Kerr shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)

Shots: Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+) Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…
October 5, 2023

Read more

Load more